Introduction {#sec1}
============

Crossed aldol additions of simple aliphatic aldehydes and ketones to electrophiles are important transformations in organic synthesis. The asymmetric version enables access to a range of interesting unusual carbohydrates and important chiral building blocks for the preparation of naturally occurring and synthetic bioactive products, including pharmaceuticals.^[@ref1]−[@ref8]^ These conversions are, however, cumbersome because of notorious side reactions such as polymerization, homo aldolization, and aldol condensation, as well as low stereoselectivity.^[@ref6],[@ref9],[@ref10]^ Enzymatic C--C bond formation mediated by aldolases is a very attractive alternative for this purpose, because of its unparalleled high stereoselectivity, avoidance of extensive protective group chemistry, and operation under mild conditions.^[@ref11]−[@ref14]^ A typical disadvantage of these enzymes is their rather narrow scope of acceptable nucleophilic substrates, whereas they tolerate a broad variety of aldehydes as the electrophilic components.

The class I [d]{.smallcaps}-fructose-6-phosphate aldolase from *E. coli* (FSA, EC 4.1.2.−) and variants with minimal mutations on selected residues within its active site, showed an unprecedented tolerance toward a large structural variety of nucleophilic and electrophilic substrates.^[@ref15]−[@ref30]^ This unveiled its extraordinary malleability beyond the boundaries of currently known aldolases. Furthermore, we recently uncovered that ethanal, propanone, butanone, and cyclopentanone are acceptable as nucleophilic components for wild-type FSA and its D6H variant when [l]{.smallcaps}- and [d]{.smallcaps}-glyceraldehyde-3-phosphate (G3P) are the electrophiles.^[@ref31]^ Nevertheless, the corresponding nonphosphorylated analogues reacted sluggishly or failed to furnish an aldol adduct.

In this work, we show that engineered variants FSA D6X^[@ref32]^ catalyze aldol additions of ethanal (**1a**), linear (**1b**--**d**), and cyclic (**1e**--**g**) simple aliphatic ketones to nonphosphorylated hydroxyaldehyde derivatives (**2a**--**c**) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), expanding the synthetic utility to rare and unusual sugar derivatives as well as related chiral building blocks.

![Panel of selected nucleophiles (**1a**--**g**) and electrophiles (**2a**--**c**).](cs-2018-02486u_0001){#fig1}

Results and Discussion {#sec2}
======================

Models of FSA wild-type in complex with the K85-[d]{.smallcaps}-fructose-6-phosphate (Fru6P) imine and the K85-dihydroxyacetone (DHA) enamine plus [d]{.smallcaps}-G3P show that these substrate intermediates can establish direct contacts with Y131, N28, and D6 residues of the active site ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). These models suggested that residue D6 can interact via hydrogen-bonding both with the CH~2~OH group of nucleophiles such as DHA and with the C2-OH of [d]{.smallcaps}-G3P, thereby influencing both the nucleophile and electrophile selectivity.^[@ref33]−[@ref35]^ To break the hydrogen bonding pattern of D6, this residue was targeted for site directed mutagenesis to obtain FSA variants with tolerance toward aldol additions of **1a** and ketones **1b**--**g** as nucleophiles to nonphosphorylated hydroxyaldehydes. Thus, individual FSA D6X variants were produced, where X = hydrophobic (A and L), polar charged (E and H), or polar uncharged (N, Q, S, and T) amino acids. Variants L107A, L163A, and A165G, which had been identified in earlier studies to benefit the nucleophile and electrophile substrate tolerance, were also screened.^[@ref16],[@ref22]^

![Molecular models of FSA-bound DHA-enamine/[d]{.smallcaps}-G3P (A) and Fru6P-imine (B) intermediates. In both cases, the D6 residue is forming two hydrogen bonds with the C2 hydroxyl group of the [d]{.smallcaps}-G3P and the hydroxymethyl group of the DHA (A), or the corresponding C3 and C5 hydroxyl groups of Fru6P (B).](cs-2018-02486u_0002){#fig2}

In the standard aldol addition of DHA to [d]{.smallcaps},[l]{.smallcaps}-G3P, only the activity of FSA D6N was found to be comparable to that of FSA wild-type (45.4 ± 0.1 U mg^--1^ vs 46.0 ± 0.1 U mg^--1^, respectively). Indeed, asparagine is isosteric to aspartate and able to establish similar hydrogen bonding interactions, which explains why no dramatic changes on the activity were observed. On the other hand, for all other D6X replacements, only very low activity was detected (between 0.72 ± 0.01 to 0.03 ± 0.01 U mg^--1^) (Table S2 in [SI](http://pubs.acs.org/doi/suppl/10.1021/acscatal.8b02486/suppl_file/cs8b02486_si_001.pdf)), confirming the critical importance of aspartate for binding of hydroxylated nucleophiles.

We began testing the panel of ketone nucleophiles **1b**--**g**, in a concentration range between 100 mM to 20% v/v, optimized for each nucleophile, with a selection of 3-hydroxyaldehyde electrophiles **2a**,**b** (80 mM) ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}) using FSA D6X variants as catalysts. Electrophiles **2a**,**b** have the advantage to shift reaction equilibrium by cyclic hemiketal formation of the product. Moreover, **2b** would introduce a chiral center as internal stereochemical reference ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). We started with 3-hydroxypropanal (**2a**) and the ketone nucleophiles in aqueous 50 mM triethanolamine buffer pH 8, similar to the conditions used in our previous communication.^[@ref31]^ D6X variants where X = A, T, or H were identified as the most effective ones for the addition of **1b** (2.0 M, 15% v/v) to **2a**, based on TLC analysis ([Table S3](http://pubs.acs.org/doi/suppl/10.1021/acscatal.8b02486/suppl_file/cs8b02486_si_001.pdf)). Compound **3b** was isolated in 32% yield using FSA D6H as catalyst ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}A, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). No reaction was detected for the addition of **1c**--**g** to **2a** with any of the FSA variants screened. Increasing the concentration of **1c**--**g** up to 20% v/v, to compensate for potentially low *K*~M~ values, was unfruitful. Furthermore, in a second round of protein engineering we combined L107A, L163A, and A165G mutations with selected D6X mutations, i.e. X = L, H, or E. However, no positive hits were found ([Table S3](http://pubs.acs.org/doi/suppl/10.1021/acscatal.8b02486/suppl_file/cs8b02486_si_001.pdf)).

![FSA Variants Catalyzed Aldol Additions of **1a**-**b, 1e**-**f** to (A) **2a**, (B) ***S*****-2b**, (C) ***R*****-2b**, and (D) **2c**](cs-2018-02486u_0004){#sch1}

###### FSA-Variant-Catalyzed Aldol Additions of **1a**,**b**,**e**,**f**, to **2a**--**c**

     Nu           E          FSA variant                  product                   isolated yield[a](#t1fn1){ref-type="table-fn"} %   ee or dr[b](#t1fn2){ref-type="table-fn"}, %
  -------- ---------------- ------------- ---------------------------------------- -------------------------------------------------- ---------------------------------------------
   **1a**       **2a**        D6L/A165G    **3a**[c](#t1fn3){ref-type="table-fn"}                          4                               --[e](#t1fn5){ref-type="table-fn"}
   **1b**       **2a**           D6H       **3b**[d](#t1fn4){ref-type="table-fn"}                          32                             \>95[f](#t1fn6){ref-type="table-fn"}
   **1a**   ***S*****-2b**       D6H       **4a**[g](#t1fn7){ref-type="table-fn"}                          27                                             97:3
   **1b**   ***S*****-2b**       D6H                       **4b**                                          25                                             97:3
   **1e**   ***S*****-2b**       D6H       **4e**[h](#t1fn8){ref-type="table-fn"}                          22                                             97:3
   **1f**   ***S*****-2b**       D6H                       **4f**                                          8                                              97:3
   **1a**   ***R*****-2b**       D6H       **5a**[i](#t1fn9){ref-type="table-fn"}                          14                                             97:3
   **1b**   ***R*****-2b**       D6H                       **5b**                                          13                                             97:3
   **1b**       **2c**           D6Q                       **6b**                                          77                             \>98[j](#t1fn10){ref-type="table-fn"}
   **1e**       **2c**           D6Q                   **6e**:**7e**                                       10                                             75:25

Product isolation and purification procedures were devised to eliminate the unconverted starting material and collecting all potential diasteroisomers. Reaction and purification conditions were not optimized.

dr determined by NMR.

α:β 1:1.

α and β anomers in equilibrium with the acyclic structure: α:β:acyclic 0.5:0.9:1.0.

ee not determined, \[α\]~D~^20^= −2.93 (*c* = 0.62 in MeOH), and this was compared with the optical rotation of the product obtained using DERA~*Ecoli*~ as catalyst: \[α\]~D~^20^= −28.6 (*c* = 1 in MeOH) (Lit.:^3^ \[α\]~D~^20^= −19.0 (*c* = 0.5, MeOH) obtained using also DERA~*Ecoli*~ as catalyst).

ee determined by chiral GC after formation of the methyl glycoside derivative against a racemic sample obtained by aldol addition of **1b** (80% v/v) to **2a** catalyzed by pyrrolidine.

α:β 1:1.

Hemiketal:acyclic adduct ratio was 85:15.

α:β 4:1.

ee determined by chiral HPLC analysis. Racemic mixture obtained by chemical synthesis using LDA methodology. Nu: nucleophile; E: electrophile.

(*S*)-3-Hydroxybutanal (*S*-**2b**) gave intense new spots on TLC in the aldol additions of: **1b** (15% v/v) using FSA D6X, where X = A, L, N, Q, S, T, E, and H; **1e** (5% v/v) using FSA D6L and D6H; and **1f** (5% v/v) using FSA D6N and D6H ([Table S3](http://pubs.acs.org/doi/suppl/10.1021/acscatal.8b02486/suppl_file/cs8b02486_si_001.pdf)). The common active variant, FSA D6H, furnished **4b**, **4e**, and **4f** in 25%, 22%, and 8% isolated yields, respectively ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}B, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}).

(*R*)-3-Hydroxybutanal (*R*-**2b**) was tested with **1b** (15% v/v) to check whether it was also substrate of FSA D6X catalysts. The best variant (i.e., FSA D6H) gave the expected lactol **5b** ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}C, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). However, lower yields were achieved as compared with *S*-**2b**, suggesting some degree of enantiomeric discrimination.^[@ref31]^

Next, we studied the addition of ethanal (**1a**) to electrophiles **2a**,**b**. It was observed that test reactions carried out at 15%--20% v/v of **1a** yielded a mixture of products arising from its nonenzymatic self-aldolization.^[@ref36]^ It is likely that the electrophilic reactivity of **1a** inactivated the enzyme and just the spontaneous chemical reaction took place. Indeed, at 100 mM concentration of **1a**, the addition to *S*- and *R*-**2b** catalyzed by FSA D6H and D6N yielded the desired aldol product. The common active variant, FSA D6H, furnished **4a** and **5a** in 27% and 14% isolated yields, respectively ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}B,C, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). In the case of **2a**, the double mutant FSA D6L/A165G was active for the addition of **1a** at 5% v/v, rendering **3a** in 4% isolated yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}).

2-Hydroxyethanal was also tested as electrophile with all nucleophiles **1a**-**g**, but it was not converted in the desired sense by any FSA variant. Thus, the *O*-protected derivative, 2-benzyloxyethanal (**2c**), was considered as synthetic equivalent, which we reported as a good electrophile for aldol additions of DHA and HA catalyzed by FSA.^[@ref22],[@ref25]^ For additions to **2c**, D6N and D6Q variants gave the highest conversions (95%) when the electrophile was **1b** (15% v/v), whereas only FSA D6Q gave acceptable conversions (53%) when it was **1e** (5% v/v) ([Table S3](http://pubs.acs.org/doi/suppl/10.1021/acscatal.8b02486/suppl_file/cs8b02486_si_001.pdf)). Accordingly, FSA D6Q furnished **6b** in 77% and **6e**+**7e** in 10% isolated yields ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}D, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). No product was formed for all other nucleophiles with any of the FSA variants.

Butanone (**1c**), 3-pentanone (**1d**) , and cyclohexanone (**1g**) were not accepted as nucleophiles by any of the FSA variants assayed with any of the electrophiles. Most probably this is due to steric interactions that difficult a proper orientation for the electrophiles and/or the nucleophiles. It is noteworthy that **1c** was tolerated as nucleophile with [l]{.smallcaps}-G3P electrophile;^[@ref31]^ however the latter is one of the most reactive electrophiles, which could compensate for the lower activity of **1c**.

In none of the reactions involving **1a** as nucleophile, neither homoaldol addition nor trimerization reactions were observed. This is in contrast with what was seen with 2-deoxy-[d]{.smallcaps}-ribose-5-phosphate aldolase *Escherichia coli* (DERA~*Ecoli*~).^[@ref37]^ Furthermore, no reactions were detected with any nucleophile/electrophile pair in control experiments performed with FSA wild-type and the inactive the inactive FSA K85M variant.

Stereoselectivity is an issue of paramount importance in these reactions. Formation of [d]{.smallcaps}-*threo* aldol adducts has been reported using catalysis by wild-type FSA and variants, practically irrespective of structural variations of nucleophile and electrophile. Moreover, the attack of FSA-enamine nucleophile invariably takes place from its *si*-face, for steric reasons and with no exceptions hitherto known.^[@ref18],[@ref19],[@ref21],[@ref24],[@ref28],[@ref29]^

Aldol adducts **4a**--**f** and **5a**,**b**, obtained by FSA D6H catalysis showed high diastereomeric purity (dr: 97:3, within the limits of high field NMR detection) ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). The internal chiral center from electrophiles **2b** and the formation of 6-membered ring hemiketals helped us to assign the absolute stereochemistry of the one or two newly formed stereocenters, which resulted to be *R*-configured, in **4a**,**b** and **5a**,**b**, and *R,R* in **4e**--**f**. Derivatives of lactol **5a** are extensively used as the chiral side chain for the synthesis of statin drugs.^[@ref37]^ The spectral data of **5a** matched those obtained from the trimerization of acetaldehyde catalyzed by DERA~*Ecoli*~. Lactol **4a** is the 5-epimer of **5a** and may constitute also an important building block for stereochemical analogs of statins.^[@ref38]^ Structural motives depicted in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"} are present in many natural products and synthetic intermediates.^[@ref8]^ Furthermore, rare sugars are important for generating novel "glycol-randomized" analogues of natural products,^[@ref5],[@ref39]−[@ref41]^ in the search for improved pharmaceutical lead compounds.^[@ref42]^

Consistent with the stereochemical outcome of adducts **4e**--**f**, an *E* configured FSA K85-enamine is imposed by the rigid ring of nucleophiles **1e** and **1f** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}).^[@ref31]^ In contrast, a *Z* configured FSA K85-enamine nucleophile is always formed with the acyclic hydroxymethylketone analogues ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A).^[@ref17]−[@ref19],[@ref28]^ In both cases, the nucleophilic attack takes place from the *si*-face, and the C=O of both *S*- and *R*-**2b** was always attacked from its *si*-face. Thus, the *anti*-configured aldol adducts were obtained with nucleophiles **1e** and **1f**, whereas the *syn* products were observed with acyclic hydroxymethylketones. The *anti*-stereochemistry from the addition of cyclopentanone to [l]{.smallcaps}-G3P catalyzed by FSA D6H, could not be unequivocally ascertained in the previous work because of the epimerization of the C-α to the carbonyl stereocenter under the reaction conditions.^[@ref31]^ In the present case, the epimerization was plausibly precluded by the in situ formation of the cyclic hemiketals: for **4e** the cyclic:acyclic ratio was 85:15, and for **4f**, no acyclic species were detected by NMR.

![Molecular models of FSA-bound **1e**-enamine/***S*****-2b** (A) and **1f**-enamine/***S*****-2b** (B) intermediates.](cs-2018-02486u_0003){#fig3}

Products **3b** and **6b**, synthesized using catalysis by FSA D6H and D6Q, respectively, showed high enantiomeric purity by chiral GC and HPLC analysis against racemic samples ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). By analogy with **4b**, it may safely be assumed that **3b** has the *R* configuration, which correlates to products **4a** and **5a**,**b**. This is consistent with the addition of hydroxymethylketone nucleophiles to **2a** catalyzed by wild-type FSA.^[@ref17],[@ref28]^ Moreover, the optical rotation of the unprotected product **9b**, \[α\]~D~^20^= −30.3 (*c* = 0.5 in CHCl~3~) (lit.:^[@ref43]^ for the *R* enantiomer \[α\]~D~^20^ = +34.0 (*c* = 0.44, CHCl~3~)) indicated that it was the *S* enantiomer.

The aldol addition of **1e** to **2c** gave a mixture of two diastereoisomers **6e**:**7e**. These can arise from (i) the lack of a precise stereofacial C=O orientation of **2c** to the enzyme-enamine complex, yielding epimers at C-β to the carbonyl,^[@ref19],[@ref26]^ or (ii) the epimerization of the C-α to the carbonyl group (i.e., the carbon tertiary center and in this case no hemiketal can be formed) under the reaction conditions (pH 8.0).^[@ref31]^ Since deuterium exchange at C-α to the carbonyl group was not detected by NMR, it was concluded that products **6e** and **7e** were obtained via the first route.

Conclusions {#sec3}
===========

We herein present FSA D6X variants that catalyze aldol additions of ethanal (**1a**) and simple ketones **1b**, **1e**, and **1f** to nonphosphorylated hydroxyaldehydes (**2c**,**d**). Substitution of D6 in wild-type FSA by amino acids such as L, N, Q, E, or H is critical to generate favorable interactions at the active site for nucleophile activation. It is noteworthy that different residues in this position with dissimilar electronic and steric properties, but not the native aspartate, rendered enzymes that were able to catalyze the addition. Because the isosteric neutral mutation D6N was active, aspartate appears to have a detrimental electronic effect for the addition of nonfunctionalized aliphatic ketones and ethanal to nonphosphorylated electrophilic substrates. Propanone (**1b**) was accepted as nucleophile component with all the selected electrophiles. Propanone is the closest analogue of hydroxypropanone, the best reported hydroxymethylketone nucleophile substrate for FSA.^[@ref24],[@ref25],[@ref28]^ The FSA D6H variant was effective with most of the reactions, accepting structurally different nucleophiles (e.g., **1a** and **1f**). Since none of the nucleophiles or electrophiles studied here has equivalent hydroxyl groups to those present in hydroxyketones, which can establish hydrogen-bond interactions with residue D6 ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}), it could be speculated that H in position 6 could have a role limiting the conformational mobility of substrates because of its larger size. This could pose a hindrance to the rotation of the C--N enamine bond and favor an adequate orientation of the approaching acceptor carbonyl, thus favoring the reaction of selected substrates.

We demonstrate that direct biocatalytic bottom up construction of rare deoxysugars and chiral intermediates is possible by the choice of aldol components using FSA as catalyst with immediate control over sites of deoxygenation. This work, along with previous studies on FSA, has shown the unprecedented versatility of this aldolase with just minimal changes in its active site. In this sense, FSA goes far beyond any known aldolase in its breath of scope for asymmetric organic synthesis, particularly when compared with dihydroxyacetone phosphate (DHAP)-dependent aldolases and DERA for their narrow nucleophile selectivity.^[@ref44]−[@ref48]^ DERA is highly selective for ethanal but showed two-orders of magnitude lower activity toward ketones such as propanone and fluoropropanone.^[@ref48]^ Further experiments to widen the synthetic scope of FSA for aldol reactions of simple aliphatic aldehydes and ketones to amino aldehydes are in progress.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acscatal.8b02486](http://pubs.acs.org/doi/abs/10.1021/acscatal.8b02486).Materials, general procedures, protein expression and purification of FSA catalysts and 2-deoxy-[d]{.smallcaps}-ribose-5-phosphate aldolase from *E. coli* (DERA*~Ecoli~*) catalyst, activity assay of FSA catalysts, preparation of racemic aldol adducts; FSA variants screening; preparative enzymatic reactions, description of physical and spectral properties and NMR spectra of the corresponding aldol adducts ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acscatal.8b02486/suppl_file/cs8b02486_si_001.pdf))
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